The Mutational Landscape in Polycythemia Vera: Phenotype, Genotype, and Prognostic Correlates

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Polycythemia Vera (PV) is characterized by JAK2 mutations, but additional non-JAK2 mutations are common.
• Understanding the role of these non-JAK2 mutations is crucial for accurate prognosis.

Purpose of the Study:

• To investigate the frequencies and prognostic impact of non-JAK2 mutations in Polycythemia Vera.
• To analyze genotype-phenotype associations and their effect on overall survival, leukemia-free survival, and myelofibrosis-free survival.

Main Methods:

• Next-generation sequencing (NGS) was performed on 319 PV patients at diagnosis, chronic phase, or transformation.
• Mutational frequencies were analyzed across different disease stages.
• Statistical analyses, including multivariable analysis, were used to assess genotype-phenotype associations and survival outcomes.

Main Results:

• Significant differences in TP53, SRSF2, IDH1, and U2AF1 mutation frequencies were observed between chronic phase, fibrotic, and leukemic PV.
• ASXL1, SRSF2, and IDH2 mutations were identified as independent risk factors for overall survival.
• SRSF2 and ASXL1 mutations, along with advanced age, were associated with inferior leukemia-free survival.
• SRSF2 mutations and abnormal karyotype significantly predicted inferior myelofibrosis-free survival.

Conclusions:

• Non-JAK2 mutations, particularly SRSF2, ASXL1, and IDH2, hold significant prognostic value in Polycythemia Vera.
• These findings support the inclusion of non-JAK2 mutations in future PV prognostic models for improved patient management.